Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54.

Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, ...

A new study looking at the replication stage of the SARS-CoV-2 virus that causes COVID-19 reveals important mechanisms in its replication that could be the foundation for new antiviral therapies.

Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of ...

Global Antiviral Drugs Industry expected to hit worth US$ 89.6 Billion at CAGR of 3.9% from forecast period 2023 to 2033 ...

BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, ...

Interim CDC guidance suggests initiating antiviral treatment with a neuraminidase inhibitor as early as possible for ...

Pfizer’s stock price rose 6% by the end of the day Wednesday to $27.18.

Innovative antiviral defense with new CRISPR tool Date: April 12, 2024 Source: Helmholtz Munich Summary: The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA ...

Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations ...

Doctors in Texas are describing the only known human case of H5N1 avian flu connected to the ongoing outbreak of the dis ...

Antiviral Combination Therapies Market is valued approximately USD 40.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than $ over the forecast period 2020-2027.